ABBVIE
A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 132
- Registration Number
- NCT03639194
- Locations
- 🇺🇸
UH Cleveland Medical Center /ID# 207561, Cleveland, Ohio, United States
🇺🇸The Ohio State University /ID# 207552, Columbus, Ohio, United States
🇺🇸Highlands Oncology Group, PA /ID# 207176, Springdale, Arkansas, United States
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2018-08-10
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 61
- Registration Number
- NCT03625505
- Locations
- 🇺🇸
Northwestern Memorial Hospital /ID# 200230, Chicago, Illinois, United States
🇺🇸Sylvester Comprehensive Cancer /ID# 200268, Miami, Florida, United States
🇺🇸David Geffen School of Medicin /ID# 200166, Los Angeles, California, United States
A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 912
- Registration Number
- NCT03607422
- Locations
- 🇺🇸
Dermatology Treatment and Research Center, PA /ID# 205473, Dallas, Texas, United States
🇺🇸Arkansas Research Trials /ID# 218469, North Little Rock, Arkansas, United States
🇺🇸Floridian Clinical Research /ID# 207433, Miami Lakes, Florida, United States
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 169
- Registration Number
- NCT03595059
- Locations
- 🇺🇸
Mary Crowley Cancer Research /ID# 214168, Dallas, Texas, United States
🇺🇸Univ Hosp Cleveland /ID# 201567, Cleveland, Ohio, United States
🇳🇱Antoni van Leeuwenhoek /ID# 222260, Amsterdam, Noord-Holland, Netherlands
Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 587
- Registration Number
- NCT03593213
- Locations
- 🇺🇸
Advanced Research Center, Inc., Anaheim, California, United States
🇺🇸California Pharmaceutical Research Institute, Inc., Costa Mesa, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Torrance, California, United States
Expanded Access to Navitoclax
- Conditions
- MyelofibrosisAcute Lymphocytic Leukemia (ALL)Lymphoblastic Lymphoma
- First Posted Date
- 2018-07-19
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- AbbVie
- Registration Number
- NCT03592576
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
- Conditions
- Bipolar I DisorderManiaDepression
- Interventions
- Drug: CariprazineDrug: Placebo
- First Posted Date
- 2018-06-29
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 901
- Registration Number
- NCT03573297
- Locations
- 🇺🇸
Synexus Clinical Research, Inc /ID# 232950, Atlanta, Georgia, United States
🇺🇸Atlanta Center for Medical Research /ID# 232832, Atlanta, Georgia, United States
🇺🇸NRC Research Institute /ID# 232741, Orange, California, United States
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 912
- Registration Number
- NCT03569293
- Locations
- 🇺🇸
Massachusetts General Hospital /ID# 200474, Boston, Massachusetts, United States
🇺🇸Dawes Fretzin, LLC /ID# 200366, Indianapolis, Indiana, United States
🇹🇷Erciyes University Medical Fac /ID# 204098, Melikgazi, Kayseri, Turkey
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 8
- Registration Number
- NCT03567616
- Locations
- 🇬🇧
Norfolk and Norwich Univ Hosp /ID# 202240, Norwich, Norfolk, United Kingdom
🇪🇸Hospital Universitario Vall d'Hebron /ID# 200967, Barcelona, Spain
🇺🇸Washington University-School of Medicine /ID# 201287, Saint Louis, Missouri, United States
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1500
- Registration Number
- NCT03568318
- Locations
- 🇺🇸
University of Pittsburgh MC /ID# 206057, Pittsburgh, Pennsylvania, United States
🇨🇦Kirk Barber Research, CA /ID# 200329, Calgary, Alberta, Canada
🇧🇪IMTR - Grand Hopital de Charleroi /ID# 202029, Loverval, Belgium